- Research
- Open access
- Published:
Exploring the factors influencing the health-related quality of life in patients experiencing adverse drug reactions: a cross-sectional study
Journal of Patient-Reported Outcomes volume 8, Article number: 112 (2024)
Abstract
Background
This study aimed to assess the factors influencing health-related quality of life (HRQoL) in patients experiencing adverse drug reactions (ADRs) at a tertiary care public sector hospital. A cross-sectional study was conducted over a period of 18 months, and included both male and female patients aged 18 years and above. Patients who visited the outpatient and inpatient departments with complaints associated with ADRs were included in this study. HRQoL data were collected using the EuroQol—5 Dimension—5 Level (EQ-5D-5L) questionnaire to assess five dimensions of health on a five-level scale. Descriptive statistics, t-tests, and analysis of variance were used to analyze the data. Multivariate regression analysis was performed to identify the potential determinants of HRQoL.
Results
A total of 316 patients were included in the study among these participants, of which 54% were female, and 65% were from rural areas. The majority (68%) of the patients had moderately severe ADRs, and 63% of the participants had an income < 2.5 lakh Indian rupees (3009 USD). The mean EQ-5D-5L and EuroQoL Visual Analog Scale (EQ VAS) scores of the study participants were 0.714 and 69.73, respectively. The variables ADR severity, income, and age showed a significant difference (p < 0.05) in HRQoL.
Conclusion
This study provides insights into HRQoL among patients with ADRs and identifies the determinants of HRQoL. The findings of this study will contribute to improving patient-centered care and optimizing patient outcomes.
Background
Adverse drug reactions (ADRs) are harmful and unintended effects of medications that occur during regular clinical use, and they can range from minor side effects to life-threatening events [1]. Literature shows 5–10% of ADRs were responsible for hospital admissions [2, 3]. In developed countries, the prevalence of hospital admissions due to ADRs was 6.3% and in developing countries 5.5% [4]. A study from India reported prevalence of ADRs was 3.7% and 0.7% ADRs were responsible for hospitalization [5]. The estimated economic burden incurred due to ADRs in Europe at €79 billion [6] and in US at $30.1 billion [7]. A study from India reported direct and indirect costs associated with ADR management were €3008 and €27,206 respectively [8].
ADRs can significantly impact health-related quality of life (HRQoL), leading to physical, emotional, and social burdens. Patients with ADRs may experience pain, fatigue, swelling, and numbness affecting their ability to perform daily activities which cause physical discomfort [9]. The experience of dealing with skin ADRs affect patients’ self-esteem and impacting emotional health leading to anxiety or depression [9, 10]. The ADRs affecting skin impacts person’s ability to interact with others leading to social avoidance [11]. Additionally, treating ADRs can be costly and time-consuming, leading to further stress and burden on patients and their families [12, 13].
Quality of life (QoL) measures an individual’s perception of their physical, mental, and social well-being concerning their health status and the treatments they receive. HRQoL is affected by various factors, including the severity and duration of illnesses, disabilities, and chronic conditions, including social and environmental factors [14, 15]. Improving HRQoL is a priority for healthcare providers, as it can impact individuals’ overall health outcomes and their ability to participate in daily activities [16]. HRQoL is relevant worldwide and is increasingly being studied and measured around the globe.
HRQoL is often measured using standardised questionnaires or surveys that ask individuals about their ability to perform activities of daily living, their emotional well-being, their social relationships, and their overall satisfaction with their health status and healthcare [17]. These measurements can provide valuable information for healthcare providers, policymakers, and researchers to assess the impact of various interventions and treatments on individuals’ QoL [14, 15].
The availability of ADR-induced QoL data may vary depending on several factors, including the specific drugs and health conditions considered [18]. However, in many countries, including India, there is often a lack of robust and systematic collection of ADR-induced QoL data. In India, the primary focus of pharmacovigilance efforts has been on monitoring and reporting adverse drug reactions rather than specifically assessing their impact on QoL. The Pharmacovigilance Programme of India (PvPI) is a government initiative that aims to collect, analyze, and monitor ADRs under the Indian Pharmacopoeia Commission (IPC) [19]. While the programme helps to identify and document adverse reactions; however, it may not consistently capture data on the impact of these reactions on patients’ QoL.
The existing literature highlights a dearth of data on the determinants of HRQoL among individuals with ADRs. Therefore, this study sought to fill this gap by investigating the factors affecting QoL in patients with ADRs. The EuroQol—5 Dimension—5 Level (EQ-5D-5L) questionnaire was used to comprehensively evaluate various QoL dimensions. The EQ-5D-5L is known for its ease of use and the calculation of quality-adjusted life years (QALYs). The QALYs generated from this study results can be used for the cost-effectiveness analysis of any new intervention focusing on ADR management or prevention.
Methods
Study design
A cross-sectional questionnaire-based study was conducted to assess QoL among patients who experienced ADRs at a tertiary care public sector hospital. The study was conducted over 18 months from December 2021 to June 2023.
Study setting and participants
Bihar is located in the eastern part of India with more than 100 million population and is India’s third most populous state. Bihar is classified as a low-income state and is one of India’s less economically developed states [20]. The primary language spoken is Hindi, however, several regional languages and dialects are also prevalent, including Bhojpuri, Maithili, and Magahi. About 11.3% of the population lives in urban areas, indicating a predominantly rural population. According to the NITI Aayog Health Index ranking, Bihar has been ranked last among the large states [21]. The state has inadequate health care infrastructure, including shortage of beds and health care professionals.
This study was conducted at the Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, a tertiary care public sector hospital that provides health services to the people of Bihar and nearby regions. Additionally, IGIMS is an ADR monitoring center (AMC) working under IPC-PvPI. The hospital accommodates 1163 beds and during 2022–2023 a total of 42,529 in-patients and 8,47,493 outpatients treated at IGIMS. More than half of the patients utilising this hospital belong below the poverty line and come from rural areas.
Patients with ADRs attending the inpatient and outpatient departments of IGIMS were identified by health care professionals and referred to the AMC for reporting ADRs to the IPC. Eligible patients were enrolled in the study based on predefined inclusion and exclusion criteria. The study participants included patients of both sexes, aged 18 years and above, who experienced ADRs. Patients with intellectual disabilities, physical handicaps, or ADRs due to intentional drug abuse were excluded from the study. Participants with incomplete information were excluded to ensure the accuracy and integrity of the data. Eligible participants were approached, provided with a detailed explanation of the study, and informed consent was obtained prior to their inclusion in the study.
Ethical considerations
The study adhered to ethical guidelines and obtained the necessary ethical approval from the institutional ethics committee of IGIMS, Patna, Bihar, India (373/IEC/IGIMS/2021). The participants’ privacy, confidentiality, and rights were protected throughout the study. Adequate measures were taken to ensure informed consent, voluntary participation, and the right to withdraw from the study.
Data collection
A trained individual administered the questionnaire through face-to-face interviews or self-administration, depending on the participant’s preference and feasibility. The interviews were conducted the same day after the patients were included in the study. All interviews took place in the hospital, and during the interviews, the patients were accompanied by their caregivers or relatives. A structured questionnaire was used to collect demographic information, medical history, and details of ADRs experienced by the participants. While collecting information regarding medical history sometimes patient caregivers responded on behalf of the patients when the patients found it difficult to recall the necessary details. Based on the Hartwig’s criteria ADRs were classified as mild, moderate or severe. Mild ADRs cause minimal discomfort and are self-limiting in nature. Moderate ADRs have a clinical impact and require treatment to manage them. Severe ADRs have a significant clinical impact and require immediate medical intervention [22].
The EQ-5D-5L Hindi questionnaire was administered to assess the participants’ QoL. The EQ-5D-5L consisted of five dimensions mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension contains five response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The EuroQol Visual Analog Scale (EQ VAS) is a self-reported measure that assesses an individual’s overall health or quality of life on a continuum from 0 to 100, with 0 indicating the worst imaginable health state and 100 representing the best possible health state [23,24,25]. The QoL assessment using the EQ-5D-5L was performed at a single time point, specifically during the occurrence of the ADR. The EQ-5D-5L questionnaire has been widely used, validated translated and culturally adapted for use across the globe, including India. This study used an Indian value set and algorithm to calculate the utility score [26, 27].
Data analysis
The collected data were entered into the Statistical Package for the Social Science (SPSS) software and descriptive statistical analysis was performed to summarise the demographic characteristics, ADR severity, and QoL scores obtained from the EQ-5D-5L. The distribution of participants across the response levels of the EQ-5D-5L was examined to assess the proportion of patients experiencing problems in each dimension. Descriptive information was presented as frequencies and percentages. To investigate differences in QoL scores between the two groups, Student’s t-test was employed. For the comparisons involving more than two groups, analysis of variance (ANOVA) was performed. Multivariate regression models were employed to identify potential determinants of QoL. A p value of < 0.05 was considered statistically significant. The statistical analyses were conducted using SPSS version 25.
Results
A total of 320 patients were initially enrolled in the study. Four participants were excluded from the analysis due to missing information, resulting in a final sample size of 316 participants.
The mean age of the participants was 41.74 years, with a standard deviation (SD) of 16.83. Among the 316 participants, 54.1% were female. Table 1 presents the sociodemographic and clinical characteristics of the participants. The largest proportion (37%) of the respondents belonged to the 31–50 years age group. In terms of residence, 65.2% of the participants were from rural areas, and 75.3% were married. Regarding education, approximately one-third (34.8%) of the respondents had completed their secondary education. The annual income measured in terms of Indian Rupees (INR) where, one lakh equals to hundred thousand. Over half (55.1%) of the participants fell into the 1–2.5 lakh INR (1203-3009USD) income category. Furthermore, the majority of the ADRs (68.04%) were classified as moderately severe. A large proportion (60.8%) of the participants were from in-patient wards and 33.5% of the ADRs were related to the antibiotic class of drugs. Over 40% of the participants were from the general medicine and medical oncology departments.
Table 2 represents the distribution of HRQoL across five dimensions and five levels. Most of the participants had no problems with mobility (47.5%) and anxiety/depression (56.3%). Most of the respondents had slight problems with selfcare (44.9%), usual activity (60.4%) and pain/discomfort (44.6%).
In Table 3, the association between QoL scores and variables is presented. The mean HRQoL scores for the EQ-5D-5L and EQ VAS were 0.71 and 69.73, respectively. Participants aged over 50 years had significantly (p < 0.001) lower QoL scores than the other age groups. The following variables showed a significant (p < 0.001) association with utility and EQ VAS scores: education, occupation, and ADR severity. Females had a higher utility score (0.73) than males additionally, single participants had a healthier score (0.80) than married individuals. A significant (p < 0.001) difference in EQ VAS scores was observed among respondents with low income.
All variables were included in the linear regression analysis, and the values are presented in Table 4. The results indicated that both gender and income significantly (p < 0.05) influenced utility and VAS scores. Moreover, the severity of ADRs was found to be a significant (p < 0.01) variable affecting the HRQoL scores.
Discussion
This study investigated the HRQoL among patients with ADRs using the EQ-5D-5L questionnaire. The findings reveal that the mean utility score (0.714 ± 0.270) was lower than the utility score of the Indian general population (0.849 ± 0.212) [26, 28] but higher than the utility score of cancer patients (0.602 ± 0.311) [29]. Additionally, the mean EQ-VAS score (69.73 ± 10.29) was lower than that of both the Indian general population (75.18 ± 16.42) [26, 28] and cancer patients (75 ± 12.3) [29]. These results indicate that patients with ADRs experience a lower level of HRQoL than the general population. Lower scores suggest a burden of health problems and reduced overall well-being among individuals affected by ADRs.
Over half of the respondents reported problems with mobility which is higher (30.3%) than the Indian general population [26]. Two studies from India reported ADRs responsible for decreased physical domain scores [30, 31], another study reported 25% of the patients with ADRs reported diminished general condition [32] and a study showed lower physical component summary patients with ADRs [33]. Patients with ADRs like muscle pain, dizziness, fatigue and numbness lead to mobility issues. The reported lower physical health among patients indicating noticeable mobility impairment leading to overall diminished QoL. Approximately 30.1% of the respondents reported slight problems related to anxiety or depression which is lower (24.8%) than the Indian general population [26]. A study from India reported patients with ADRs reported diminished psychological health [30], and another study reported a quarter of the participants’ mood or enjoyment of life was impacted [32]. A cross-sectional study reported a lower mental component summary among patients with ADRs [33], and a study revealed depression and anxiety prevalence was higher among ADR patients than the general population [34]. A higher reporting of mobility problems and anxiety/depression is consistent among ADR patients. This highlights the significant impact of ADRs on patients’ QoL and the importance of addressing both physical and mental health aspects in ADR management.
The study findings revealed a significant association (p < 0.001) between HRQoL scores and age, indicating that older age is a contributing factor to impaired QoL. Specifically, the HRQoL scores decreased with increasing age, which is consistent with previous studies conducted in India [26, 28, 35], as well as studies conducted in other countries [36, 37]. The consistent findings across different studies and countries further support the robustness and generalisability of the age-related impact on HRQoL. Indeed, the older age group is more susceptible to having multiple diseases and a higher prevalence of mental health issues. Furthermore, mental health issues, such as depression, anxiety, and cognitive decline are more prevalent among older adults [38]. These conditions may further compound the impact of ADRs on the individual’s overall QoL and well-being. Tailored interventions, including medication management, mental health support, and comprehensive care, may help mitigate the impact of ADRs and enhance the overall QoL in this population.
The study findings demonstrated a significant (p < 0.05) impact of participants’ income on HRQoL. These results align with previous studies that have also investigated the influence of income on QoL [39, 40]. Indeed, studies have demonstrated a significant association between insufficient income and high anxiety levels [41, 42]. Specifically, the findings indicate that individuals with lower incomes tend to experience a low level of QoL. Low income could pose various challenges and limitations that may negatively affect multiple aspects of a person’s life, including access to healthcare, living conditions, and social support. These factors might collectively contribute to a diminished quality of life.
The study findings indicate that the severity of ADRs significantly (p < 0.001) influences HRQoL. These results are consistent with previous studies conducted on various diseases, which have consistently shown that disease severity is associated with QoL [43,44,45]. When ADRs are more severe, they may have a greater impact on an individual’s physical and psychological well-being, resulting in a lower HRQoL. Higher levels of symptom burden, functional impairment, pain, and discomfort associated with severe ADRs can adversely affect different dimensions of a person’s quality of life. Understanding the impact of ADR severity on HRQoL is essential for healthcare professionals to accurately assess the consequences of adverse reactions and tailor appropriate interventions. By considering the severity of ADRs and their association with QoL, healthcare providers can prioritise effective management strategies, minimise the impact of ADRs on patients’ well-being, and optimise their overall treatment outcomes.
The study results might be useful in developing patient-centred interventions and policy guidelines to improve patient-reported outcomes. The study highlights the importance of considering individual demographics of patients, such as age, income and ADR severity along with treatment plans to provide a personalised approach that may improve patient outcomes. The study results may enable more patient-centred care, improved treatment decision-making, and enhanced drug safety monitoring, ultimately leading to improved healthcare outcomes and better QoL for affected individuals.
The study results were reliable and replicable; however, the study has some limitations. The study was conducted at a public sector hospital, where most of the population came from rural areas. This could impact the QoL scores as access to health care diminished and patients may have had to travel long hours to reach the hospital. The reliance on self-reported measures may have introduced response bias and subjectivity in QoL assessments. Collecting QoL data only once during the occurrence of the ADR may not have captured long-term or post resolution QoL changes. The EQ-5D-5L is a generic scale and may not capture all disease-specific or condition-specific variables. Differences in understanding and interpreting the questionnaire items can lead to variability in responses. This is particularly relevant in populations with varying levels of health literacy and education. Being in a hospital setting can cause stress and anxiety for patients, which might influence their responses to the survey. The presence of caregivers or relatives might influence patients’ responses.
Conclusion
These findings emphasise the need for interventions and support measures to address the specific challenges faced by the patients and improve their HRQoL. Strategies to improve HRQoL include addressing underlying health conditions, improving access to healthcare, providing social and emotional support, and addressing environmental factors that may impact individuals’ health and well-being. Therefore, healthcare providers need to identify and manage ADRs promptly to improve the QoL of patients and promote better health outcomes.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Aronson JK, Ferner RE (2005) Clarification of terminology in drug safety. Drug safety 28:851–870. https://doi.org/10.2165/00002018-200528100-00003
Komagamine J (2024) Prevalence of urgent hospitalizations caused by adverse drug reactions: a cross-sectional study. Sci Rep 14:6058
Oscanoa TJ, Lizaraso F, Carvajal A (2017) Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 73:759–770
Angamo MT, Chalmers L, Curtain CM, Bereznicki LR (2016) Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf 39:847–857
Ramesh M, Pandit J, Parthasarathi G (2003) Adverse drug reactions in a south Indian hospital—their severity and cost involved. Pharmacoepidemiol Drug Saf 12:687–692
Commission of the European Communities (2008) Commission staff working document Annex 2 of the report on the impact assessment of strengthening and rationalizing EU Pharmacovigilance. https://health.ec.europa.eu/document/download/bc08b27f-4850-4b1c-9832-bb326d1f68ae_en?filename=pharmacovigilance-ia-vol2_en.pdf. Accessed 1 June 2024
Sultana J, Cutroneo P, Trifirò G (2013) Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacotherapeutics 4:S73–S77
Pattanaik S, Dhamija P, Malhotra S, Sharma N, Pandhi P (2009) Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. Br J Clin Pharmacol 67:363–369
Du R, Yang H, Zhu J, Zhou H, Ma L, Getu MA, Chen C, Wang T (2022) Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: a qualitative study. Asia-Pacific J Oncol Nurs 9:100115
Suh HJ, Florez A, Sacristan V, Rodriguez Martinez A, Fernandez F, Vilanova-Trillo L, Constenla M, Pereiro M (2021) Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new. Int J Dermatol 60:208–216
Jui-Chun CHAN, Yun-Hsiang LEE, Chien-Ying LIU, Hui-Hsuan SHIH, Pei-Kwei TSAY, Woung-Ru TANG (2019) A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy. J Nurs Res 27:e51
Sendekie AK, Kasahun AE, Limenh LW, Dagnaw AD, Belachew EA (2023) Clinical and economic impact of adverse drug reactions in hospitalised patients: prospective matched nested case–control study in Ethiopia. BMJ open. https://doi.org/10.1136/bmjopen-2023-073777
Jordan S, Logan PA, Panes G, Vaismoradi M, Hughes D (2018) Adverse drug reactions, power, harm reduction, regulation and the ADRe profiles. https://doi.org/10.3390/pharmacy6030102. Pharmacy
Palermo TM, Long AC, Lewandowski AS, Drotar D, Quittner AL, Walker LS (2008) Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. J Pediatr Psychol 33:983–996. https://doi.org/10.1093/jpepsy/jsn038
Revicki DA, Kleinman L, Cella D (2022) A history of health-related quality of life outcomes in psychiatry. Dialog Clin Neurosci 16:127–135. https://doi.org/10.31887/DCNS.2014.16.2/drevicki
Megari K (2013) Quality of life in chronic disease patients. Health Psychol Res https://doi.org/10.4081/hpr.2013.e27
Hernández-Segura N, Marcos-Delgado A, Pinto-Carral A, Fernández-Villa T, Molina AJ (2022) Health-Related Quality of Life (HRQOL) Instruments and mobility: a systematic review. Int J Environ Res Public Health https://doi.org/10.3390/ijerph192416493
Alomar MJ (2014) Factors affecting the development of adverse drug reactions. Saudi Pharm J 22:83–94. https://doi.org/10.1016/j.jsps.2013.02.003
Kumar A, Ahuja J, Shrivastava TP, Kumar V, Kalaiselvan V (2018) Statistical signal process in R language in the pharmacovigilance programme of India. Therapeutic Innov Regul Sci 52:329–333. https://doi.org/10.1177/2168479017728988
World Bank Group (2016) Bihar - Poverty, growth and inequality (English). India state briefs Washington, DC. http://documents.worldbank.org/curated/en/781181467989480762/Bihar-Poverty-growth-and-inequality. Accessed 1 June 2024
Niti aayog (2024) National Institution for Transforming India.https://social.niti.gov.in/hlt-ranking. Accessed 1 June 2024
Hartwig SC, Siegel J, Schneider PJ (1992) Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 49:2229–2232
Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727–1736. https://doi.org/10.1007/s11136-011-9903-x
Kind P (1996) The EuroQoL instrument: an index of health-related quality of life. Qual life Pharmacoeconomics Clin Trials 2:191–201
Kind P, Brooks R, Rabin R (2005) EQ-5D concepts and methods. A developmental history. Springer Dordrecht. https://doi.org/10.1007/1-4020-3712-0
Jyani G, Prinja S, Garg B, Kaur M, Grover S, Sharma A et al (2023) Health-related quality of life among Indian population: the EQ-5D population norms for India. J Global Health. https://doi.org/10.7189/jogh.13.04018
Euro QL (2023) India value set SPSS. https://euroqol.org/wp-content/uploads/2022/03/India_valueset_SPSS.txt. Accessed 1 July 2023
Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK et al (2022) Development of an EQ-5D value set for India using an extended design (DEVINE) study: the Indian 5-level version EQ-5D value set. Value Health 25:1218–1226. https://doi.org/10.1016/j.jval.2021.11.1370
Gupta N, Pandey AK, Dimri K, Jyani G, Goyal A, Prinja S (2022) Health-related quality of life among breast cancer patients in India. Support Care Cancer 30:9983–9990. https://doi.org/10.1007/s00520-022-07395-7
Chawla S, Kumar S (2017) Adverse drug reactions and their impact on quality of life in patients on antipsychotic therapy at a tertiary care center in Delhi. Indian J Psychol Med 39:293–298
Krishnarajan D, Sivasakthi K, Ariyamol R, Kumar DN, Varghese S (2021) A prospective observational study of chemotherapy-induced adverse drug reaction and the quality of life in cancer patients in a tertiary care hospital. J Cancer Res Ther 17:530–536
Kekäle M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 1733–1740
Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, Lönnmark E, Long L, Rosen S (2019) The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes 17:1–15
Martini M, Di Taranto M, Höfer V, Worm M, Bilò MB (2023) Health-related quality of life and mental health in drug hypersensitivity reactions and drug-induced anaphylaxis: a systematic review and meta-analysis. J Allergy Clin Immunol Pract
Wadasadawala T, Mohanty SK, Sen S, Khan PK, Pimple S, Mane JV et al (2023) Health-Related Quality of Life (HRQoL) using EQ-5D-5L: value set derived for Indian breast cancer cohort. Asian Pac J Cancer Prev 24:1199–1207. https://doi.org/10.31557/apjcp.2023.24.4.1199
Wong EL, Xu RH, Cheung AW (2019) Health-related quality of life among patients with hypertension: population-based survey using EQ-5D-5L in Hong Kong SAR, China. https://doi.org/10.1136/bmjopen-2019-032544. BMJ open
Abedini MR, Bijari B, Miri Z, Shakhs Emampour F, Abbasi A (2020) The quality of life of the patients with diabetes type 2 using EQ-5D-5 L in Birjand. Health Qual Life Outcomes 18:1–9. https://doi.org/10.1186/s12955-020-1277-8
Petrova NN, Khvostikova DA (2021) Prevalence, structure, and risk factors for mental disorders in older people. Adv Gerontol 11:409–415. https://doi.org/10.1134/S2079057021040093
Zhang S, Xiang W (2019) Income gradient in health-related quality of life—the role of social networking time. Int J Equity Health. https://doi.org/10.1186/s12939-019-0942-1. 18:1– 0
Thangiah G, Said MA, Majid HA, Reidpath D, Su TT (2020) Income inequality in quality of life among rural communities in Malaysia: a case for immediate policy consideration. Int J Environ Res Public Health 17:8731. https://doi.org/10.3390/ijerph17238731
Thomson RM, Igelström E, Purba AK, Shimonovich M, Thomson H, McCartney G et al (2022) How do income changes impact on mental health and wellbeing for working-age adults? A systematic review and meta-analysis. Lancet Public Health 7:515–528. https://doi.org/10.1016/S2468-2667(22)00058-5
Amin MA, Ahmed M, Nahin S, Kakoly NS (2022) Assessment of depression and anxiety among admitted people with heart disease conditions: a cross-sectional hospital-based study in a Bangladeshi population during the COVID-19. Front Psychiatry. https://doi.org/10.3389/fpsyt.2022.895224
Poudel AN, Zhu S, Cooper N, Roderick P, Alwan N, Tarrant C et al (2021) Impact of Covid-19 on health-related quality of life of patients: a structured review. PLoS ONE. https://doi.org/10.1371/journal.pone.0259164
Yavuz Daglioglu EB, Cadirci D, Aksoy M (2020) Effects of disease severity on quality of life in patients with psoriasis. Dermatol Ther. https://doi.org/10.1111/dth.14422
O’Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD et al (2020) Disease severity and quality of life in patients with idiopathic pulmonary fibrosis: a cross-sectional analysis of the IPF-PRO registry. Chest 157:1188–1198. https://doi.org/10.1016/j.chest.2019.11.042
Acknowledgements
We thank the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, for providing the necessary infrastructural support. A humble thanks to all the study participants.
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
Conceptualization: K.M., S.D.; Data curation, Formal Analysis: M.K., G.P.; Investigation, Methodology, Project administration: V.R.; Writing—original draft: G.P.; Writing-review and editing: All authors.
Corresponding author
Ethics declarations
Ethical approval
This study was performed adhering to the principles of the Helsinki Declaration. Ethical permission was obtained from the institutional ethics committee of Indira Gandhi Institute of Medical Sciences, Patna (Date 13/12/2021, Number 373/IEC/IGIMS/2021).
Consent to participate
Informed consent was obtained from all the study participants.
Consent for publication
Not applicable.
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Pavan, G., Kumar, M., Murti, K. et al. Exploring the factors influencing the health-related quality of life in patients experiencing adverse drug reactions: a cross-sectional study. J Patient Rep Outcomes 8, 112 (2024). https://doi.org/10.1186/s41687-024-00790-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s41687-024-00790-0